Patents by Inventor Beidi XU

Beidi XU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLIN K DEGRADER AND USE THEREOF
    Publication number: 20260209211
    Abstract: Provided are a Cyclin K degrader compound, and preparation method and uses thereof. Specifically, provided are the compounds represented by formula (I) and pharmaceutical compositions thereof, and use thereof for preventing and/or treating Cyclin K-related diseases.
    Type: Application
    Filed: December 13, 2023
    Publication date: July 23, 2026
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Beidi XU, Zhiyong YU, Xiaojun HAN, Xin CHANG, Qingchong QIU, Ling ZHANG, Yao WANG, Nanhai HE, Xiaohan WANG, Xiangyu XIA
  • PD-L1 antagonist compound
    Patent number: 12583839
    Abstract: Provided are a compound of Formula (I) and a pharmaceutical composition thereof, as well as a method for using the compounds of Formula (I) to prevent and/or treat immune-related disorders.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: March 24, 2026
    Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Zhiyong Yu, Pan Li, Beidi Xu, Yu Zhou, Wei Pang, Qiaodong Wen, Yongqiang Shi, Zhao Sun, Meng Lv
  • CYCLIN K DEGRADER
    Publication number: 20240368147
    Abstract: The disclosure provides a compound of formula (I) and pharmaceutical compositions thereof. The compound of formula (I) of the present disclosure can be used as a degradation agent of cyclin K (CyclinK protein), and can be used to prevent or treat diseases related to CyclinK protein.
    Type: Application
    Filed: August 25, 2022
    Publication date: November 7, 2024
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Beidi XU, Qingchong QIU, Zhiyong YU, Nanhai HE, Bin JI, Ling ZHANG, Xiaohan WANG, Xiangyu XIA, Zhao SUN
  • PD-L1 antagonist compound
    Patent number: 12091398
    Abstract: Provided is a compound represented by formula (I) and a pharmaceutical composition thereof, as well as a method for using a compound represented by formula (I) to prevent and/or treat immune-related disorders.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: September 17, 2024
    Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Pan Li, Beidi Xu, Qiaodong Wen, Enguang Feng, Ji Wang, Yang Lu, Yu Zhou, Zhiyong Yu, Zhiying Huang
  • PD-L1 ANTAGONIST COMPOUND
    Publication number: 20230054028
    Abstract: Provided are a compound of Formula (I) and a pharmaceutical composition thereof, as well as a method for using the compounds of Formula (I) to prevent and/or treat immune-related disorders.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 23, 2023
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Zhiyong YU, Pan LI, Beidi XU, Yu ZHOU, Wei PANG, Qiaodong WEN, Yongqiang SHI, Zhao SUN, Meng LV
  • PD-L1 ANTAGONIST COMPOUND
    Publication number: 20220227733
    Abstract: Provided is a compound represented by formula (I) and a pharmaceutical composition thereof, as well as a method for using a compound represented by formula (I) to prevent and/or treat immune-related disorders.
    Type: Application
    Filed: February 20, 2020
    Publication date: July 21, 2022
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Pan LI, Beidi XU, Qiaodong WEN, Enguang FENG, Ji WANG, Yang LU, Yu ZHOU, Zhiyong YU, Zhiying HUANG